Quarry LP’s Coherus Oncology CHRS Stock Holding History

Quarry LP’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-15,572	Closed	-$25.5K	–	2199
2025 Q3	$25.5K	Buy	+15,572	New	+$17.3K	0.01%	1258

Other funds holding CHRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Quarry LP's CHRS Position: Q4 2025 in Review

Quarry LP sold out of Coherus Oncology (CHRS) in Q4 2025, closing a stake of 15,572 shares — an estimated $25.5K sold.

Quarry LP first reported a position in CHRS in Q3 2025 and held it in 1 quarter. The position peaked at $25.5K in Q3 2025. 127 funds tracked by Wall St. Rank hold CHRS as of Q4 2025.

Quarry LP reported no remaining Coherus Oncology position as of Q4 2025 after selling out during the quarter.
Quarry LP sold 15,572 Coherus Oncology shares in Q4 2025, an estimated $25.5K.
Quarry LP first reported a position in Coherus Oncology in Q3 2025 and held it in 1 quarter.
Quarry LP's Coherus Oncology position peaked at $25.5K in Q3 2025.
127 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2025.

Based on Quarry LP's 13F filing for Q4 2025, filed 13 Feb 2026.